New immunotherapies targeting the PD-1 pathway

Jordan M. Chinai, Murali Janakiram, Fuxiang Chen, Wantao Chen, Mark Kaplan, Xingxing Zang

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Ligands from the B7 family bind to receptors of the CD28 family, which regulate early T cell activation in lymphoid organs and control inflammation and autoimmunity in peripheral tissues. Programmed death-1 (PD-1), a member of the CD28 family, is an inhibitory receptor on T cells and is responsible for their dysfunction in infectious diseases and cancers. The complex mechanisms controlling the expression and signaling of PD-1 and programmed death ligand 1 (PD-L1) are emerging. Recently completed and ongoing clinical trials that target these molecules have shown remarkable success by generating durable clinical responses in some cancer patients. In chronic viral infections, preclinical data reveal that targeting PD-1 and its ligands can improve T cell responses and virus clearance. There is also promise in stimulating this pathway for the treatment of autoimmune and inflammatory disorders.

Original languageEnglish (US)
Pages (from-to)587-595
Number of pages9
JournalTrends in Pharmacological Sciences
Volume36
Issue number9
DOIs
StatePublished - Sep 12 2015

Fingerprint

T-cells
Immunotherapy
Ligands
Costimulatory and Inhibitory T-Cell Receptors
Reticuloendotheliosis virus
T-Lymphocytes
Viruses
Virus Diseases
Chemical activation
Autoimmunity
Tissue
Communicable Diseases
Neoplasms
Molecules
Clinical Trials
Inflammation
Therapeutics

Keywords

  • cancer
  • immunotherapy
  • PD-1
  • PD-L1
  • PD-L2
  • viral infection

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

New immunotherapies targeting the PD-1 pathway. / Chinai, Jordan M.; Janakiram, Murali; Chen, Fuxiang; Chen, Wantao; Kaplan, Mark; Zang, Xingxing.

In: Trends in Pharmacological Sciences, Vol. 36, No. 9, 12.09.2015, p. 587-595.

Research output: Contribution to journalArticle

Chinai, Jordan M. ; Janakiram, Murali ; Chen, Fuxiang ; Chen, Wantao ; Kaplan, Mark ; Zang, Xingxing. / New immunotherapies targeting the PD-1 pathway. In: Trends in Pharmacological Sciences. 2015 ; Vol. 36, No. 9. pp. 587-595.
@article{85e1cafebf734686b0aa95bbfbb6701b,
title = "New immunotherapies targeting the PD-1 pathway",
abstract = "Ligands from the B7 family bind to receptors of the CD28 family, which regulate early T cell activation in lymphoid organs and control inflammation and autoimmunity in peripheral tissues. Programmed death-1 (PD-1), a member of the CD28 family, is an inhibitory receptor on T cells and is responsible for their dysfunction in infectious diseases and cancers. The complex mechanisms controlling the expression and signaling of PD-1 and programmed death ligand 1 (PD-L1) are emerging. Recently completed and ongoing clinical trials that target these molecules have shown remarkable success by generating durable clinical responses in some cancer patients. In chronic viral infections, preclinical data reveal that targeting PD-1 and its ligands can improve T cell responses and virus clearance. There is also promise in stimulating this pathway for the treatment of autoimmune and inflammatory disorders.",
keywords = "cancer, immunotherapy, PD-1, PD-L1, PD-L2, viral infection",
author = "Chinai, {Jordan M.} and Murali Janakiram and Fuxiang Chen and Wantao Chen and Mark Kaplan and Xingxing Zang",
year = "2015",
month = "9",
day = "12",
doi = "10.1016/j.tips.2015.06.005",
language = "English (US)",
volume = "36",
pages = "587--595",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - New immunotherapies targeting the PD-1 pathway

AU - Chinai, Jordan M.

AU - Janakiram, Murali

AU - Chen, Fuxiang

AU - Chen, Wantao

AU - Kaplan, Mark

AU - Zang, Xingxing

PY - 2015/9/12

Y1 - 2015/9/12

N2 - Ligands from the B7 family bind to receptors of the CD28 family, which regulate early T cell activation in lymphoid organs and control inflammation and autoimmunity in peripheral tissues. Programmed death-1 (PD-1), a member of the CD28 family, is an inhibitory receptor on T cells and is responsible for their dysfunction in infectious diseases and cancers. The complex mechanisms controlling the expression and signaling of PD-1 and programmed death ligand 1 (PD-L1) are emerging. Recently completed and ongoing clinical trials that target these molecules have shown remarkable success by generating durable clinical responses in some cancer patients. In chronic viral infections, preclinical data reveal that targeting PD-1 and its ligands can improve T cell responses and virus clearance. There is also promise in stimulating this pathway for the treatment of autoimmune and inflammatory disorders.

AB - Ligands from the B7 family bind to receptors of the CD28 family, which regulate early T cell activation in lymphoid organs and control inflammation and autoimmunity in peripheral tissues. Programmed death-1 (PD-1), a member of the CD28 family, is an inhibitory receptor on T cells and is responsible for their dysfunction in infectious diseases and cancers. The complex mechanisms controlling the expression and signaling of PD-1 and programmed death ligand 1 (PD-L1) are emerging. Recently completed and ongoing clinical trials that target these molecules have shown remarkable success by generating durable clinical responses in some cancer patients. In chronic viral infections, preclinical data reveal that targeting PD-1 and its ligands can improve T cell responses and virus clearance. There is also promise in stimulating this pathway for the treatment of autoimmune and inflammatory disorders.

KW - cancer

KW - immunotherapy

KW - PD-1

KW - PD-L1

KW - PD-L2

KW - viral infection

UR - http://www.scopus.com/inward/record.url?scp=84941313624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941313624&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2015.06.005

DO - 10.1016/j.tips.2015.06.005

M3 - Article

VL - 36

SP - 587

EP - 595

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 9

ER -